A medical technology company enabling precision medicine to become a reality in neuroscience research and development
Location: Switzerland
Total raised: $18.79M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.11.2025 | - | $18.79M | - |
Mentions in press and media 7
| Date | Title | Description |
| 24.02.2026 | Leclercq American Capital LLC invests in Indivi.io, a Swiss specialist in digital biomarkers for neurology | Thomas Leclercq Leclercq American Capital LLC The US-based firm belonging to entrepreneur Thomas Leclercq is strengthening its exposure to “data biotechnology” by taking a strategic stake in Indivi.io NEWARK, DE, UNITED STATES, February 24,... |
| 14.01.2026 | Executive hires to help startups scale | As part of its executive transition plan, SOPHiA Genetics announced the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, succeeding Jurgi Camblong, co-founder and CEO. Ross, who currently serves as Presiden... |
| 20.11.2025 | Indivi Nets $16.8M for Alzheimer's Biomarker Discovery | Indivi secured CHF 15 million. This will boost Alzheimer's drug development. The company will launch a trial in 2026. It seeks better biomarkers. This aims to improve treatment efficacy. The funds will advance precision medicine. This targe... |
| 17.11.2025 | Indivi secures CHF 15 million | Based in Basel, Indivi is developing digital biomarkers and digital health technologies (DHT) and precision measurements to accelerate neuroscience drug development and personalized care in neurodegenerative and neuroimmune diseases. Their... |
| 12.11.2025 | Indivi: CHF15 Million Secured To Advance Biomarker Discovery In Alzheimer’s Drug Development | Indivi, a Basel-based Tech Bio company specializing in precision medicine for neuroscience, announced the successful closing of a CHF 15 million investment round led by Ava Investors. The new funding will accelerate the validation and deplo... |
| 17.09.2025 | Seasoned leaders step into key roles at life sciences startups | Melodia Therapeutics, a Forty51 Ventures company, developing a next generation DPP1 inhibitor with best-in-class potential for inflammatory conditions, has appointed Jonathan Talbot as Chief Executive Officer. He brings over 15 years of in... |
| 09.04.2024 | Neue Führungspersonen mit Start-up und Scale-up-Erfahrung | Seit Anfang April ist Tim Pfister Chief Business Development Officer bei CLEVERON. Pfister ist vor allem aufgrund seiner Rollen bei den Diagnostikfirmen Livet und ender diagnostics bekannt geworden. Beide Startups hatte er mitgegründet und... |